hVIVO plc (LON:HVO - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 10.34 ($0.14) and traded as low as GBX 9.60 ($0.13). hVIVO shares last traded at GBX 10 ($0.14), with a volume of 1,549,023 shares changing hands.
Analyst Ratings Changes
A number of research firms recently weighed in on HVO. Shore Capital reiterated a "buy" rating and issued a GBX 35 price objective on shares of hVIVO in a research report on Tuesday, July 22nd. Peel Hunt reiterated an "add" rating and issued a GBX 21 price objective on shares of hVIVO in a research report on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, hVIVO presently has an average rating of "Buy" and a consensus target price of GBX 28.
Read Our Latest Stock Report on hVIVO
hVIVO Trading Down 1.0%
The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The business's fifty day moving average is GBX 10.31 and its 200 day moving average is GBX 13.64. The stock has a market cap of £68.03 million, a PE ratio of 638.71 and a beta of 0.97.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
